Targeting CARM1 with EZM2302, a CARM1-specific inhibitor, significantly inhibits CARM1-mediated GATAD2A methylation, cell cycle gene transcription, cell cycle progression, and breast tumor growth (Figure 8). Here, CARM1 is linked to breast neoplasm.